Novozymes Statistics

Total Valuation

Novozymes has a market cap or net worth of EUR 23.57 billion. The enterprise value is 26.30 billion.

Market Cap	23.57B
Enterprise Value	26.30B

Important Dates

The next confirmed earnings date is Tuesday, May 5, 2026.

Earnings Date	May 5, 2026
Ex-Dividend Date	Mar 24, 2026

Share Statistics

Current Share Class	412.17M
Shares Outstanding	n/a
Shares Change (YoY)	+68.00%
Shares Change (QoQ)	-0.32%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	27.44%
Float	346.58M

Valuation Ratios

The trailing PE ratio is 40.39 and the forward PE ratio is 23.93.

PE Ratio	40.39
Forward PE	23.93
PS Ratio	5.67
PB Ratio	2.17
P/TBV Ratio	n/a
P/FCF Ratio	29.04
P/OCF Ratio	19.30
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.20, with an EV/FCF ratio of 32.40.

EV / Earnings	45.06
EV / Sales	6.33
EV / EBITDA	17.20
EV / EBIT	27.55
EV / FCF	32.40

Financial Position

The company has a current ratio of 0.72, with a Debt / Equity ratio of 0.28.

Current Ratio	0.72
Quick Ratio	0.43
Debt / Equity	0.28
Debt / EBITDA	1.96
Debt / FCF	3.70
Interest Coverage	14.08

Financial Efficiency

Return on equity (ROE) is 5.30% and return on invested capital (ROIC) is 5.56%.

Return on Equity (ROE)	5.30%
Return on Assets (ROA)	3.81%
Return on Invested Capital (ROIC)	5.56%
Return on Capital Employed (ROCE)	7.07%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	374,626
Profits Per Employee	52,586
Employee Count	11,098
Asset Turnover	0.26
Inventory Turnover	2.48

Taxes

In the past 12 months, Novozymes has paid 159.80 million in taxes.

Income Tax	159.80M
Effective Tax Rate	21.50%

Stock Price Statistics

The stock price has decreased by -8.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-8.60%
50-Day Moving Average	50.05
200-Day Moving Average	53.26
Relative Strength Index (RSI)	50.37
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Novozymes had revenue of EUR 4.16 billion and earned 583.60 million in profits. Earnings per share was 1.25.

Revenue	4.16B
Gross Profit	2.31B
Operating Income	961.70M
Pretax Income	743.40M
Net Income	583.60M
EBITDA	1.54B
EBIT	961.70M
Earnings Per Share (EPS)	1.25

Balance Sheet

The company has 275.30 million in cash and 3.01 billion in debt, giving a net cash position of -2.73 billion.

Cash & Cash Equivalents	275.30M
Total Debt	3.01B
Net Cash	-2.73B
Net Cash Per Share	n/a
Equity (Book Value)	10.86B
Book Value Per Share	23.30
Working Capital	-758.10M

Cash Flow

In the last 12 months, operating cash flow was 1.22 billion and capital expenditures -409.80 million, giving a free cash flow of 811.70 million.

Operating Cash Flow	1.22B
Capital Expenditures	-409.80M
Depreciation & Amortization	574.80M
Net Borrowing	1.21B
Free Cash Flow	811.70M
FCF Per Share	n/a

Margins

Gross margin is 55.45%, with operating and profit margins of 23.13% and 14.04%.

Gross Margin	55.45%
Operating Margin	23.13%
Pretax Margin	17.88%
Profit Margin	14.04%
EBITDA Margin	36.96%
EBIT Margin	23.13%
FCF Margin	19.52%

Dividends & Yields

This stock pays an annual dividend of 0.87, which amounts to a dividend yield of 1.71%.

Dividend Per Share	0.87
Dividend Yield	1.71%
Dividend Growth (YoY)	4.76%
Years of Dividend Growth	1
Payout Ratio	69.00%
Buyback Yield	-68.00%
Shareholder Yield	-66.29%
Earnings Yield	2.48%
FCF Yield	3.44%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novozymes has an Altman Z-Score of 4.19 and a Piotroski F-Score of 6.

Altman Z-Score	4.19
Piotroski F-Score	6